<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913315</url>
  </required_header>
  <id_info>
    <org_study_id>CQU023</org_study_id>
    <nct_id>NCT00913315</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis</brief_title>
  <acronym>ESTTFCP</acronym>
  <official_title>Efficacy Study of Tamsulosin and Tolterodine Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Lower Urinary Tract Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fuling Central Hospital of Chongqing City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether tamsulosin and tolterodine are effective in
      the treatment of men with lower urinary tract symptoms and chronic prostatitis/chronic pelvic
      pain syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common disorder in urological
      clinics. Most of the clinically CP/CPPS are to some extent associated with storage
      (irritative) symptoms, such as increased frequency, urgency, and nocturia, namely many
      patients with CP/CPPS have overactive bladder symptoms. Alpha-blocker therapy has been
      advocated as a treatment modality for CP/CPPS. Some trials showed a statistically and likely
      clinically significant treatment effect, while other trials showed no benefit. Therefore,
      tamsulosin combination with tolterodine treatment for CP/CPPS may be more effective than
      tamsulosin single.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institutes of Health Chronic Prostatitis Symptom Index</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak urinary flow rate</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostatitis</condition>
  <arm_group>
    <arm_group_label>tolterodine + tamsulosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tamsulosin + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolterodine</intervention_name>
    <description>4 mg of tolterodine ER</description>
    <arm_group_label>tolterodine + tamsulosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamsulosin</intervention_name>
    <description>0.4 mg of tamsulosin once a day for 8 weeks</description>
    <arm_group_label>tolterodine + tamsulosin</arm_group_label>
    <arm_group_label>tamsulosin + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo once a day for 8 weeks</description>
    <arm_group_label>tamsulosin + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosis of CP/CPPS based on the classification of US National Institutes of Health,
             aged 18-45 years

          2. total score of at least 12 on the National Institutes of Health Chronic Prostatitis
             Symptom Index (NIH-CPSI)

          3. urinary score of at least 4 on the CPSI

          4. subjects who anticipate improving symptoms

        Exclusion Criteria:

          1. previous treatment with any other alpha-adrenergic receptor blocker and antimuscarinic
             agents for symptoms of CP/CPPS or for any other reason

          2. those who had had previous urinary tract infection with the last year

          3. those who had been treat or were taking medication that could affect lower urinary
             tract function

          4. those who met the criteria for chronic bacterial prostatitis after lower urinary tract
             localization studies

          5. those who had other significant medical problems
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Chen, MD</last_name>
    <phone>86-23-89011122</phone>
    <email>cy0324@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Urology, the First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaohou Wu, MD</last_name>
      <phone>86-2389011122</phone>
      <email>93404840@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Nickel JC, Krieger JN, McNaughton-Collins M, Anderson RU, Pontari M, Shoskes DA, Litwin MS, Alexander RB, White PC, Berger R, Nadler R, O'Leary M, Liong ML, Zeitlin S, Chuai S, Landis JR, Kusek JW, Nyberg LM, Schaeffer AJ; Chronic Prostatitis Collaborative Research Network. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med. 2008 Dec 18;359(25):2663-73. doi: 10.1056/NEJMoa0803240.</citation>
    <PMID>19092152</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>June 4, 2009</last_update_submitted>
  <last_update_submitted_qc>June 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Yong Chen</name_title>
    <organization>Urology department , Fuling Central Hospital of Chongqing</organization>
  </responsible_party>
  <keyword>prostatitis</keyword>
  <keyword>Adrenergic alpha-Antagonists</keyword>
  <keyword>tolterodine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Prostatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

